February 22, 2017 / 12:10 PM / 7 months ago

BRIEF-Prometic says PBI-4050 shows encouraging efficacy in IPF study

Feb 22 (Reuters) - Prometic Life Sciences Inc

* Prometic’s PBI-4050 continues to demonstrate early evidence of efficacy following completion of idiopathic pulmonary fibrosis phase 2 clinical trial

* Prometic life sciences inc - early evidence of efficacy of pbi-4050 as a monotherapy and in combination with one of commercially available drugs confirmed

* Prometic life sciences inc - pbi-4050 continues to be very well tolerated, whether used alone or in combination with nintedanib or pirfenidone

* Prometic life sciences inc - intend to initiate in q2 2017 pivotal phase 2/3 ipf clinical trial Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below